Inclisiran is a small interfering RNA, or siRNA, therapy that has the potential to lower LDL-C by preventing the production of a protein, proprotein
convertase subtilisin/kexin type 9, or PCSK9, in the liver.
Repatha is a human monoclonal antibody that inhibits proprotein
convertase subtilisin/kexin type 9 (PCSK9).
TUESDAY, July 23, 2019 (HealthDay News) -- Patients with rejected or abandoned prescriptions for proprotein
convertase subtilisin kexin type 9 inhibitors (PCSK9i) have a significantly increased risk for cardiovascular events than those with paid prescriptions, according to a study published online July 23 in Circulation: Cardiovascular Quality and Outcomes.
Jointly developed by Amgen Astellas and Astellas in Japan, Repatha[R] is a human lgG2 monoclonal antibody that inhibits proprotein
convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the ability of hepatic LDL receptors to remove LDL-C, or "bad" cholesterol, from the blood.
Praluent is the first PCSK9 (proprotein
convertase subtilisin/kexin type 9) and only PCSK9 inhibitor available in two doses with two levels of efficacy as a single 1 ml injection (75 mg and 150 mg) once every two weeks.
The update was undertaken because new evidence has emerged since the publication of the 2013 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guideline about additional cholesterol-lowering agents including ezetimibe and proprotein
convertase sub-tilisin/kexin type 9 (PCSK9) inhibitors.
The Further Cardiovascular outcomes Research with PCSK9 inhibition in subject with elevated risk (Fourier) trial was the pivotal efficacy and safety study for the proprotein
convertase subtilisin- kexin type 9 (PCSK9) inhibitor evolocumb (Repatha) and enrolled patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of at least 70 mg/d.
turicata; transcripts encoding for proprotein
convertase and glycoprotein B were identified in both species."
The analysis showed that patients with metabolic syndrome (MetS) treated with the proprotein
convertase subtilisin--kexin type 9 (PCSK9) inhibitor evolocumab in the FOURIER study had a statistically significant 17% relative risk reduction in the study's primary efficacy endpoint compared with placebo, while those without MetS had an 11% relative risk reduction that did not reach statistical significance, Prakash Deedwania, MD, said at the annual congress of the European Society of Cardiology.
These drugs work by inactivating a liver protein called proprotein
convertase subtilisin/kexin type 9 or PCSK9.
Novel agents include the proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors (that have shown to lead to a reduction in CVD morbidity), mipomersen, cholesterol ester transfer protein (CETP) inhibitors and bempedoic acid.